The development of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection was well-received by patients and physicians, as viral clearance is associated with improved liver-related and overall survivals.1,2 Despite this remarkable advance, it is expected that HCV-induced cirrhosis and its complications will continue to increase for many years.3,4 In fact, modeling studies predict that by 2030 almost one-half of those with HCV in the United States will have cirrhosis.